2016 Fiscal Year Final Research Report
Elucidation of the mechanism contributing to atherosclerosis progression via FGF21 and insulin resistance in cardio-renal syndrome
| Project/Area Number |
26860636
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 心腎連関 / 慢性腎臓病 / FGF21 / FGF23 / 動脈硬化 / 拡張障害 / 収縮障害 |
|---|
| Outline of Final Research Achievements |
Fibroblast growth factor (FGF) 19/21/23 is an endocrine FGF. FGF23 regulates mineral metabolism and FGF21 is a metabolic hormone that is crucial in glucose and lipid homeostasis. We assessed the relationships between the serum FGF21/23 levels measured by ELISA and vascular parameters, renal outcomes and cardiac function in CKD patients.
We showed that the serum FGF21 level is significantly associated with vascular disorders, including endothelial dysfunction and vascular calcification, independent of the glucose and lipid profiles. We demonstrated that the serum FGF21 level is significantly associated with the renal outcomes. In addition, the serum FGF21 and FGF23 concentrations were independently associated with the diastolic and systolic functions, respectively.
|
| Free Research Field |
腎臓病学
|
